Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BY-NC-NDInternal Medicine

Successful Treatment of Varicella Zoster Encephalitis in a Sarcopenic Obese Patient after Acyclovir-induced Acute Kidney Injury: The Necessity of Individualized Dosing

  • Yugo Takahashi
  • Akihiro Tsukahara
  • Takuya Nishina
  • Hiroo Yoshikawa
  • Takashi Uzu
Read full textPDFDOICite

Abstract

Acyclovir (ACV) is the first-line agent for varicella zoster virus (VZV) encephalitis. Acute kidney injury (AKI) remains a clinical concern. We report the case of a sarcopenic obese woman with VZV encephalitis. She developed AKI 2 days after receiving intravenous ACV based on her actual body weight. After temporarily discontinuing ACV and confirming recovery of the renal function, ACV was restarted at a dose based on her ideal body weight. The patient recovered without any further complications. This case underscores the importance of dose adjustment of water-soluble medications, such as ACV, in obese patients, particularly in those with sarcopenic obesity.

Related

  1. Conservative management of crowned dens syndrome and atlas posterior arch resection: Two successful experiences of individualized treatment.
    Yulin Liu, Xinye Li, Zhenyu Wang +3
    Experimental and therapeutic medicinePeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  2. Successful treatment of lamotrigine-induced Stevens-Johnson syndrome with upadacitinib.
    Amishi Taneja, Jacob Kingsley, Severine Z Cao +2
    JAAD case reportsPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  3. Successful Treatment of Recalcitrant Pyoderma Gangrenosum with Baricitinib in Two Patients with Rheumatoid Arthritis.
    Christian Ciolfi, Bernd Raffeiner, Margherita Zen +3
    Dermatology practical & conceptualPeer-reviewedCC BY-NCFull textEpidemiology & public healthEurope PMC
  4. Successful Treatment of an Atypical Mycobacterial Exit Site Infection in a Patient on Peritoneal Dialysis: A Case Report
    Michael Shye, Anita D Sircar, Ramya Malchira +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Two pediatric type II achalasia cases complicated by candidal and eosinophilic esophagitis: Successful peroral endoscopic myotomy treatment
    Fabio Rotondo, Antonio Marseglia, Anna Locatelli +5
    JPGN reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{takahashi2026successful,
  title = {{Successful Treatment of Varicella Zoster Encephalitis in a Sarcopenic Obese Patient after Acyclovir-induced Acute Kidney Injury: The Necessity of Individualized Dosing}},
  author = {Yugo Takahashi and Akihiro Tsukahara and Takuya Nishina and Hiroo Yoshikawa and Takashi Uzu},
  journal = {Internal Medicine},
  year = {2026},
  month = aug,
  doi = {10.2169/internalmedicine.6635-25},
  url = {https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6635-25/_article},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Successful Treatment of Varicella Zoster Encephalitis in a Sarcopenic Obese Patient after Acyclovir-induced Acute Kidney Injury: The Necessity of Individualized Dosing
AU  - Yugo Takahashi
AU  - Akihiro Tsukahara
AU  - Takuya Nishina
AU  - Hiroo Yoshikawa
AU  - Takashi Uzu
PY  - 2026
DA  - 2026/08/15
JO  - Internal Medicine
DO  - 10.2169/internalmedicine.6635-25
UR  - https://www.jstage.jst.go.jp/article/internalmedicine/65/16/65_6635-25/_article
AB  - Acyclovir (ACV) is the first-line agent for varicella zoster virus (VZV) encephalitis. Acute kidney injury (AKI) remains a clinical concern. We report the case of a sarcopenic obese woman with VZV encephalitis. She developed AKI 2 days after receiving intravenous ACV based on her actual body weight. After temporarily discontinuing ACV and confirming recovery of the renal function, ACV was restarted at a dose based on her ideal body weight. The patient recovered without any further complications. This case underscores the importance of dose adjustment of water-soluble medications, such as ACV, in obese patients, particularly in those with sarcopenic obesity.
SN  - 1349-7235
SN  - 0918-2918
ER  -